Invited Speaker
Your present position:
Jian Zhou
Affiliation：Zhongshan Hospital, Fudan University
Position：President of Zhongshan Hospital, Fudan University；
Jian Zhou
Current Position:
President of Zhongshan Hospital, Fudan University; Professor and Doctoral Advisor. He is a member of the Chinese Academy of Medical Sciences (CAMS), recipient of the Distinguished Young Scholars Fund (National Science Foundation of China), a laureate of multiple national talent programs including the National "Ten Thousand Talents" Program as a Leading Talent in Science and Technology Innovation, and the leader of the Innovation Team on Precision Medicine for Liver Cancer Metastasis and Recurrence under the Ministry of Science and Technology (MOST), China. Professor Zhou also serves as the incoming Chair of the Chinese Society of Clinical Oncology (CSCO), President of the Asia-Pacific Primary Liver Cancer Expert Alliance (APPLE) (the first mainland Chinese scholar to hold this position), Vice President and Secretary-General of the Chinese Medical Doctor Association (CMDA) Surgeons' Branch, and former Chair of the Liver Cancer Professional Committee of the Chinese Anti-Cancer Association.
Career and Contributions:
Professor Zhou has dedicated over 30 years to clinical and translational research in liver cancer, accumulating experience from over 10,000 liver resections and more than 3,000 liver transplants. Internationally, he pioneered the dual-donor "living related liver + discarded liver" transplantation approach, performed Asia’s first Associating Liver Partition and Portal vein ligation for Staged hepatectomy (ALPPS) procedure, and established a surgical protocol for ALPPS, achieving globally leading case volume and survival rates for hepatocellular carcinoma treated with this method. His team, led alongside Academician Fan Jia, developed an miRNA-based early diagnostic model for liver cancer, which has since been commercialized as a testing kit, included in health insurance, and widely applied in clinical settings. Zhou also challenged the prevailing international view that early post-operative recurrence of liver cancer is always ancestral, and he established the China Liver Cancer Staging (CNLC) system tailored to the characteristics of the Chinese population. As Vice Chair and Secretary-General of the Expert Committee, he co-authored the Guidelines for Diagnosis and Treatment of Primary Liver Cancer (2017 Edition), and the 2019 and 2022 updates, now applied in over 300 hospitals nationwide, significantly advancing liver cancer treatment standards in China.
Awards and Publications:
Professor Zhou has won the National Science and Technology Progress Award (China) five times (once as the first contributor and twice as the second contributor). He has led 26 major projects, including those under the National 863 Program, National Natural Science Foundation of China (NSFC) key projects, NSFC Original Exploration Program, and the National Key R&D Program. He has published over 500 papers in prestigious journals such as Cell, Nature, Annals of Surgery, Journal of Clinical Oncology, Gastroenterology, and Hepatology, with 129 SCI-indexed articles as first or corresponding author (including co-authored papers), achieving an H-index of 79. Zhou holds 18 authorized invention patents, all of which have been successfully commercialized. His honors include the Tan Jiazhen Life Science Innovation Award, Qiu Fazu General Surgery Youth Award, Wu Mengchao Medical Youth Fund Award, National May 1st Labor Medal, Exemplary Physician of the Nation, Shanghai Science and Technology Elite, and Shanghai Outstanding Talent Award.
Current Position:
President of Zhongshan Hospital, Fudan University; Professor and Doctoral Advisor. He is a member of the Chinese Academy of Medical Sciences (CAMS), recipient of the Distinguished Young Scholars Fund (National Science Foundation of China), a laureate of multiple national talent programs including the National "Ten Thousand Talents" Program as a Leading Talent in Science and Technology Innovation, and the leader of the Innovation Team on Precision Medicine for Liver Cancer Metastasis and Recurrence under the Ministry of Science and Technology (MOST), China. Professor Zhou also serves as the incoming Chair of the Chinese Society of Clinical Oncology (CSCO), President of the Asia-Pacific Primary Liver Cancer Expert Alliance (APPLE) (the first mainland Chinese scholar to hold this position), Vice President and Secretary-General of the Chinese Medical Doctor Association (CMDA) Surgeons' Branch, and former Chair of the Liver Cancer Professional Committee of the Chinese Anti-Cancer Association.
Career and Contributions:
Professor Zhou has dedicated over 30 years to clinical and translational research in liver cancer, accumulating experience from over 10,000 liver resections and more than 3,000 liver transplants. Internationally, he pioneered the dual-donor "living related liver + discarded liver" transplantation approach, performed Asia’s first Associating Liver Partition and Portal vein ligation for Staged hepatectomy (ALPPS) procedure, and established a surgical protocol for ALPPS, achieving globally leading case volume and survival rates for hepatocellular carcinoma treated with this method. His team, led alongside Academician Fan Jia, developed an miRNA-based early diagnostic model for liver cancer, which has since been commercialized as a testing kit, included in health insurance, and widely applied in clinical settings. Zhou also challenged the prevailing international view that early post-operative recurrence of liver cancer is always ancestral, and he established the China Liver Cancer Staging (CNLC) system tailored to the characteristics of the Chinese population. As Vice Chair and Secretary-General of the Expert Committee, he co-authored the Guidelines for Diagnosis and Treatment of Primary Liver Cancer (2017 Edition), and the 2019 and 2022 updates, now applied in over 300 hospitals nationwide, significantly advancing liver cancer treatment standards in China.
Awards and Publications:
Professor Zhou has won the National Science and Technology Progress Award (China) five times (once as the first contributor and twice as the second contributor). He has led 26 major projects, including those under the National 863 Program, National Natural Science Foundation of China (NSFC) key projects, NSFC Original Exploration Program, and the National Key R&D Program. He has published over 500 papers in prestigious journals such as Cell, Nature, Annals of Surgery, Journal of Clinical Oncology, Gastroenterology, and Hepatology, with 129 SCI-indexed articles as first or corresponding author (including co-authored papers), achieving an H-index of 79. Zhou holds 18 authorized invention patents, all of which have been successfully commercialized. His honors include the Tan Jiazhen Life Science Innovation Award, Qiu Fazu General Surgery Youth Award, Wu Mengchao Medical Youth Fund Award, National May 1st Labor Medal, Exemplary Physician of the Nation, Shanghai Science and Technology Elite, and Shanghai Outstanding Talent Award.
Contact us
Contact us
Submission consultation：Tsssh2024_rcv@163.com
VISA/Registration/ Room Reservation consultation: Tsssh2024_cons@163.com